Our approach is different from the other works [10,11,12] in several ways: (1) We divided breast cancer patients into two groups according to the existence of somatic mutations in TP53, whereas the other works treated breast cancer patients as a whole or divided them into predicted molecular subtypes. This evidence concerns the gene TP53 and breast cancer.